2-(3,4-Difluoro-phenoxy)-N-hydroxy-acetamidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(3,4-Difluoro-phenoxy)-N-hydroxy-acetamidine
• 英文别名: 2-(3,4-difluorophenoxy)-N'-hydroxyethanimidamide
• 化学式: C₈H₈F₂N₂O₂
• 分子量: 202.161
• InChiKey: QXSZRHSQQRAMNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(3,4-Difluoro-phenoxy)-N-hydroxy-acetamidine 、 在 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二乙二醇二甲醚 为溶剂， 生成 4-(4-{2-[tert-Butoxycarbonyl-((R)-2-hydroxy-2-pyridin-3-yl-ethyl)-amino]-ethyl}-phenylsulfamoyl)-N-{2-(3,4-difluoro-phenoxy)-1-[(E)-hydroxyimino]-ethyl}-benzimidic acid
  参考文献：
  名称：

  Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective β3 adrenergic receptor agonist antiobesity agents

  摘要：

  Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta(3) adrenergic receptor (AR) agonists. The 4-trifluormethoxy substituted 5-benzyl oxadiazole 5f has an EC50 of 8 nM in the beta(3) AR agonist assay with 100-fold selectivity over beta(1) and beta(2) AR binding inhibition activity. Its oral bioavailability in dogs is 30 +/- 4%, with a half-life of 3.8 +/- 0.4 h. In the anesthetized rhesus, 5f evoked a dose-dependent glycerolemia (ED50Gly = 0.15 mg/kg): Under these conditions a heart rate increase of 15% was observed at a dose level of 10 mg/kg. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00268-7

文献信息

• Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective β3 adrenergic receptor agonist antiobesity agents
  作者：Tesfaye Biftu、Dennis D Feng、Gui-Bai Liang、Howard Kuo、Xiaoxia Qian、Elizabeth M Naylor、Vincent J Colandrea、Mari R Candelore、Margaret A Cascieri、Lawrence F Colwell、Michael J Forrest、Gary J Hom、D.Euan MacIntyre、Ralph A Stearns、Catherine D Strader、Matthew J Wyvratt、Michael H Fisher、Ann E Weber

  DOI：10.1016/s0960-894x(00)00268-7

  日期：2000.7

  Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta(3) adrenergic receptor (AR) agonists. The 4-trifluormethoxy substituted 5-benzyl oxadiazole 5f has an EC50 of 8 nM in the beta(3) AR agonist assay with 100-fold selectivity over beta(1) and beta(2) AR binding inhibition activity. Its oral bioavailability in dogs is 30 +/- 4%, with a half-life of 3.8 +/- 0.4 h. In the anesthetized rhesus, 5f evoked a dose-dependent glycerolemia (ED50Gly = 0.15 mg/kg): Under these conditions a heart rate increase of 15% was observed at a dose level of 10 mg/kg. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.